The Central Drugs Standard Control Organisation (CDSCO) has approved Wegovy as India's first injectable Glucagon-Like Peptide-1 (GLP-1) receptor agonist for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). MASH is a progressive form of fatty liver disease that leads to inflammation and fibrosis of the liver. Wegovy has been approved for adults with moderate to advanced fibrosis (stages F2–F3), to be used together with changes in diet and lifestyle.